JPWO2020181062A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020181062A5 JPWO2020181062A5 JP2021543386A JP2021543386A JPWO2020181062A5 JP WO2020181062 A5 JPWO2020181062 A5 JP WO2020181062A5 JP 2021543386 A JP2021543386 A JP 2021543386A JP 2021543386 A JP2021543386 A JP 2021543386A JP WO2020181062 A5 JPWO2020181062 A5 JP WO2020181062A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- mhc class
- acid sequence
- sequence identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814721P | 2019-03-06 | 2019-03-06 | |
| US62/814,721 | 2019-03-06 | ||
| PCT/US2020/021138 WO2020181062A1 (en) | 2019-03-06 | 2020-03-05 | T-cell modulatory multimeric polypeptides and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522405A JP2022522405A (ja) | 2022-04-19 |
| JP2022522405A5 JP2022522405A5 (https=) | 2023-03-09 |
| JPWO2020181062A5 true JPWO2020181062A5 (https=) | 2023-03-09 |
Family
ID=72338760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543386A Pending JP2022522405A (ja) | 2019-03-06 | 2020-03-05 | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20220105162A1 (https=) |
| EP (1) | EP3935080A4 (https=) |
| JP (1) | JP2022522405A (https=) |
| WO (1) | WO2020181062A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116970059A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| CA3061614A1 (en) | 2017-04-28 | 2018-11-01 | The Regents Of The University Of Colorado, A Body Corporate | Methods of treating rheumatoid arthritis using rna-guided genome editing of hla gene |
| TW201920249A (zh) | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| CN117222664A (zh) * | 2021-01-29 | 2023-12-12 | 拜耳动物保健有限责任公司 | 用于破坏自身耐受的疫苗组合物 |
| JP2024517658A (ja) * | 2021-04-21 | 2024-04-23 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節ポリペプチド及びその使用方法 |
| WO2022226037A1 (en) * | 2021-04-21 | 2022-10-27 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof |
| CN117396229A (zh) * | 2021-04-21 | 2024-01-12 | Cue生物制药股份有限公司 | Mhc ii类t细胞调节多肽及其使用方法 |
| JP2024517475A (ja) * | 2021-05-10 | 2024-04-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 自己免疫を治療するための操作されたｈｌａ対立遺伝子 |
| KR20240038974A (ko) * | 2021-07-29 | 2024-03-26 | 난트셀, 인크. | 바이러스 감염 및 암의 예방 및 치료를 위한 변형된 t 세포 수용체 |
| WO2025111562A1 (en) * | 2023-11-22 | 2025-05-30 | Cue Biopharma, Inc. | Mhc class ii protein complexes |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| JPH10503379A (ja) * | 1994-07-29 | 1998-03-31 | デイド・インターナショナル・インコーポレーテッド | Ｍｈｃ複合体およびその用途 |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| WO2003062370A2 (en) | 2001-07-19 | 2003-07-31 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| EP1996937A4 (en) | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| CA2748314C (en) | 2009-02-03 | 2018-10-02 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| WO2012007951A1 (en) * | 2010-07-15 | 2012-01-19 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides |
| PL3157552T3 (pl) * | 2014-06-18 | 2020-05-18 | Albert Einstein College Of Medicine | Polipeptydy syntac i ich zastosowania |
| ES3055030T3 (en) * | 2015-05-06 | 2026-02-09 | Uti Lp | Nanoparticle compositions for sustained therapy |
| KR20190044029A (ko) * | 2016-05-18 | 2019-04-29 | 알버트 아인슈타인 컬리지 오브 메디슨, 인크. | 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법 |
| MX2019005497A (es) * | 2016-11-09 | 2019-11-18 | Uti Lp | Moleculas de pmhc de clase ii recombinantes. |
| CN116970059A (zh) * | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| IL269000B2 (en) * | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
-
2020
- 2020-03-05 EP EP20765925.1A patent/EP3935080A4/en not_active Withdrawn
- 2020-03-05 WO PCT/US2020/021138 patent/WO2020181062A1/en not_active Ceased
- 2020-03-05 JP JP2021543386A patent/JP2022522405A/ja active Pending
-
2021
- 2021-08-05 US US17/394,972 patent/US20220105162A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,201 patent/US20250242005A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500855A5 (https=) | ||
| Todd et al. | A molecular basis for genetic susceptibility to insulin-dependent diabetes mellitus | |
| Spies et al. | Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer | |
| McMichael et al. | Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes. | |
| Todd et al. | A molecular basis for MHC class II—associated autoimmunity | |
| Terhorst et al. | Further structural studies of the heavy chain of HLA antigens and its similarity to immunoglobulins. | |
| Robb et al. | Sequence of the COOH-terminal hydrophilic region of histocompatibility antigens HLA-A2 and HLA-B7 | |
| JPWO2020181062A5 (https=) | ||
| JP2019522466A5 (https=) | ||
| Rosloniec et al. | Identification of MHC class II and TCR binding residues in the type II collagen immunodominant determinant mediating collagen-induced arthritis | |
| JP2019512222A5 (https=) | ||
| Parham et al. | HLA-A, B, C: patterns of polymorphism in peptide-binding proteins | |
| Campbell et al. | MHC genes in autoimmunity | |
| Bach et al. | High affinity presentation of an autoantigenic peptide in type I diabetes by an HLA class II protein encoded in a haplotype protecting from disease | |
| JPWO2020243315A5 (https=) | ||
| JPWO2020180501A5 (https=) | ||
| Cook et al. | Structural Studies on the Murine Ia Alloantigens: IV. NH2-Terminal Sequence Analysis of Allelic Products of the IA and IE/C Subregions | |
| EP0286447B1 (en) | Method and agents relating to prophylactic treatment of autoimmune diseases | |
| JPWO2020132297A5 (https=) | ||
| WO1995011702A1 (en) | Prokaryotic expression of mhc proteins | |
| Hogan et al. | Localization and characterization of serologic epitopes on HLA-A2 | |
| Routsias et al. | Polymorphic structural features of modelled HLA-DQ molecules segregate according to susceptibility or resistance to IDDM | |
| JPWO2020132138A5 (https=) | ||
| JPH10507908A (ja) | 自己免疫病の治療に役立つ化合物を同定する方法 | |
| Kaul et al. | The role of major histocompatibility complex genes in myasthenia gravis and experimental autoimmune myasthenia gravis pathogenesis |